依达拉奉联合氯吡格雷对比单用氯吡格雷治疗急性脑梗死疗效与安全性的Meta分析

发布时间：2018-06-05 07:07

本文选题：依达拉奉 + 氯吡格雷　；参考：《中国药房》2016年33期

【摘要】：目的:系统评价依达拉奉联合氯吡格雷对比单用氯吡格雷治疗急性脑梗死的疗效和安全性,为临床提供循证参考。方法:计算机检索Pub Med、Medline(Ovid)、相关期刊论文、中文科技期刊数据库、万方数据库,收集依达拉奉联合氯吡格雷(试验组)对比单用氯吡格雷(对照组)治疗急性脑梗死的随机对照试验(RCT),对纳入研究进行质量评价和资料提取后,采用Rev Man 5.3统计软件进行Meta分析。结果:共纳入18项RCT,合计1 611例患者。Meta分析结果显示,试验组患者总有效率[OR=4.07,95%CI(3.01,5.49),P0.001]、基本痊愈率[OR=2.09,95%CI(1.68,2.59),P0.001]、日常生活能力评分[MD=13.42,95%CI(11.62,15.23),P0.001]均显著高于对照组,神经功能缺损评分显著低于对照组[MD=-6.20,95%CI(-8.14,-4.26),P0.001],差异均有统计学意义。两组患者治疗后期复发率[OR=0.52,95%CI(0.24,1.13),P=0.10]和不良反应发生率比较,差异均无统计学意义。结论:依达拉奉联合氯吡格雷治疗急性脑梗死的疗效显著优于单用氯吡格雷,可改善患者的神经功能缺损状态,提高日常生活能力,在安全性方面两者相当。
[Abstract]:Objective: to evaluate the efficacy and safety of Edaravone combined with clopidogrel in the treatment of acute cerebral infarction. Methods: Pub Medline Medline Ovidna, full text database of Chinese periodicals, database of Chinese sci-tech periodicals, database of Wanfang were searched by computer. A randomized controlled trial of Edaravone combined with clopidogrel (trial group) was collected for the treatment of acute cerebral infarction compared with clopidogrel (control group). Meta analysis was carried out with Rev Man 5.3 statistical software. Results: a total of 18 RCTs were included. The results of Meta-analysis showed that the total effective rate of the patients in the trial group [OR4.0795 CIQ 3.01C 5.49P0.001], the basic recovery rate [OR2.0995CII 1.68 2.59P0.001], the ADL score [MD13.4295CII 11.62 15.23P0.001] were significantly higher than those in the control group. The neurological deficit score was significantly lower than that in the control group (P 0.001). There was no significant difference in the recurrence rate and the incidence of adverse reactions between the two groups. Conclusion: Edaravone combined with clopidogrel is superior to clopidogrel in the treatment of acute cerebral infarction.
【作者单位】：武汉大学医院;武汉大学中南医院;
【分类号】：R743.3

【相似文献】